Investor presentation

RNS Number : 8523T
Shield Therapeutics PLC
30 March 2021
 

 

Shield Therapeutics plc

("Shield Therapeutics" or the "Company")

 

Investor presentation

 

London, UK, 30 March 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that Tim Watts, Chief Executive Officer, will present at the Proactive One2One Virtual Investor Forum on Thursday 8 April 2021.

 

Shield will be one of three companies presenting on the evening, each having a presentation slot followed by Q&A, with the webinar taking place from 6.00pm. Investors can register to attend here:  

https://event.webinarjam.com/register/1024/gwwg2hxq9

 

No new material information will be disclosed at the event and t he presentation will be made available on the Company's website shortly after the event here:    https://www.shieldtherapeutics.com/investors/presentations    

 

 

 

For further information, please contact:

 

Shield Therapeutics plc

+44 (0) 191 511 8500

Tim Watts (CEO)




Peel Hunt LLP - Nominated Adviser and Joint Broker

  +44 (0) 20 7148 8900

James Steel / Christopher Golden




finnCap Ltd - Joint Broker

  +44 (0) 20 7220 0500

Geoff Nash / Alice Lane / Matthew Radley




Walbrook PR - Financial PR & IR Adviser

+44 (0) 20 7933 8780

Paul McManus / Lianne Cawthorne

or shield@walbrookpr.com

 

 

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

 

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

 

For more information, please visit  www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAJLMITMTTTBMB

Companies

Shield Therapeutics (STX)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today